Optimet

OptiMet was a French biotechnology company focused on the discovery and development of a new class of oral small molecule drugs for the treatment of metabolic diseases. The company's primary research centered on the activation of AMP-activated protein kinase (AMPK), a key enzyme often referred to as the 'metabolic gatekeeper' that regulates energy balance at both the cellular and whole-body levels. By targeting AMPK, OptiMet aimed to develop therapies for Type 2 diabetes and obesity that could improve insulin sensitivity and glucose metabolism. Founded by experts in metabolic research, the company sought to leverage its deep understanding of AMPK signaling to address significant unmet needs in metabolic health.